PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.04
D/E ratio exceeding 1.5x Biotechnology median of 0.01. Howard Marks would check for debt covenant compliance and refinancing risks.
8.07
Dangerously high net debt exceeding 1.5x Biotechnology median of 1.55. Michael Burry would check for debt covenant compliance and refinancing risks.
No Data
No Data available this quarter, please select a different quarter.
12.53
Current ratio exceeding 1.5x Biotechnology median of 4.90. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
No Data
No Data available this quarter, please select a different quarter.